-
July 15, 2024 News about the new triple combination of vanza triple drugsThe acceptance of the US Food and Drug Administration's (FDA) application for the new vanza triple drug combination...
-
February 21, 2024 Positive results from pivotal trials of new triple CFTR Modulator “Vanza triple”Vertex Pharmaceuticals announced positive results from its once-daily new CFTR Modulator vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”) program. The new...
-
November 24, 2023 Approval of Kaftrio-Kalydeco for CF children 2-5y.o. in EuropeGood news for CF children!European Commission approved Kaftrio in combination with Kalydeco for the treatment of children with...
-
October 30, 2023 HIT-CF program for rare mutations – August 2023 UpdateResubmission of the "Choices" clinical trial to CTIS, after its initial rejection, is being prepared by the European...
-
September 25, 2023 CHMP positive opinion for Kaftrio/Kalydeco in CF children 2-5 y.o.European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the...
-
June 16, 2022 Promising news for long-term benefits of innovative treatments in Cystic Fibrosis & new clinical studies on rare mutationsPromising news for long-term benefits of innovative treatments in Cystic Fibrosis & new clinical studies on rare mutationsVery...
